Save time and get answers to complex questions with AI chat
How does insurance coverage impact nivolumab's duration?Drugpatentwatch market analysis industry today?Guselkumab patent expiration?When oxcarbazepine patent expired?Dabrafenib and trametinib price?
See the DrugPatentWatch profile for methotrexate
Methotrexate requires extra caution in patients over 65 due to age-related declines in kidney function, liver metabolism, and bone marrow reserve, which increase toxicity risks. Renal clearance drops naturally with age, leading to higher drug accumulation and side effects like severe myelosuppression or mucositis.[1][2]
Unadjusted doses in frail elderly have led to fatal outcomes, including pancytopenia and infections. Guidelines recommend starting at low doses (e.g., 7.5 mg/week for RA) with CBC, renal, and liver tests every 1-4 weeks initially.[1][2]
Younger adults tolerate higher doses better due to robust organ function; elderly need individualized dosing via Cockcroft-Gault GFR estimates and often lower weekly maxima (10-15 mg).[3][4]
ACR and EULAR guidelines flag elderly as high-risk, mandating informed consent on toxicity. No absolute age cutoff, but caution ramps up at 65+ or with 2+ geriatric syndromes (frailty, polypharmacy).[2][4] Sources [1]: Drugs.com - Methotrexate Precautions [2]: UpToDate - Methotrexate in Rheumatoid Arthritis [3]: FDA Label - Methotrexate [4]: American College of Rheumatology Guidelines
Other Questions About Methotrexate :